HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

lanreotide (Somatuline)

somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours; do not confuse with BIM 23014 C; amino acid sequence given in first source

Also Known As:

Somatuline; 188Re-lanreotide; 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide; BIM 23014; BIM 23014C; BIM-23014; DC 13-116; DC-13-116; DC13-116; L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide; Lasa Brand of Lanreotide Acetate; Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2; Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2; Somatulin; Somatulina; lanreotide acetate; lanreotide-SR; naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide; naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2; L-Threoninamide, 3-(1-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide

Networked: 400 relevant articles (87 outcomes, 90 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Colao, Annamaria: 15 articles (11/2014 - 03/2002)
2.	Pivonello, Rosario: 11 articles (04/2011 - 04/2003)
3.	Lombardi, Gaetano: 9 articles (04/2011 - 03/2002)
4.	Colao, A: 8 articles (06/2010 - 01/2000)
5.	Lombardi, G: 8 articles (03/2009 - 01/2000)
6.	Raderer, M: 8 articles (02/2002 - 03/2000)
7.	Kurtaran, A: 7 articles (02/2002 - 03/2000)
8.	Virgolini, I: 7 articles (02/2002 - 03/2000)
9.	Caron, Philippe: 6 articles (08/2015 - 02/2006)
10.	Auriemma, Renata S: 6 articles (04/2011 - 03/2006)

Related Diseases

1.	Acromegaly 09/01/2014 - "Lanreotide ATG provided hormonal control and improved both health-related quality of life and acromegaly symptoms in most patients; it also reduced tumour volume to a clinically significant extent in studies of primary therapy. " 01/01/2008 - "Subcutaneous lanreotide ATG was an effective and generally well tolerated treatment in patients with acromegaly in well designed trials and extension studies of up to 4 years' duration. " 01/01/2008 - "Subcutaneous lanreotide ATG was an effective and generally well tolerated treatment in patients with acromegaly in well designed trials and extension studies of up to 4 years duration. " 02/01/2006 - "This 3-year study shows that lanreotide Autogel is effective in controlling GH/IGF-1 hypersecretion and is well tolerated during long-term treatment of patients with acromegaly." 01/01/2009 - "Lanreotide is an effective treatment for active acromegaly. "
2.	Neoplasms (Cancer) 09/01/1998 - "In this study, we treated a group of patients with gastrointestinal endocrine tumors with lanreotide to assess its therapeutic efficacy and tolerability. " 02/01/2009 - "Lanreotide has been administered to patients with CRPC within a novel treatment concept, with the aim of targeting not only cancer cells but also various factors secreted in the tumor cell milieu that confer protection from apoptosis. " 04/01/2014 - "The aim of the study was to better characterize the effects of primary lanreotide Autogel treatment on tumor size in patients with GH-secreting macroadenomas. " 01/01/2010 - "Twenty-two studies were found to be eligible for the final analysis, in which tumor size was measured as an end-point for lanreotide treatment. " 04/01/2002 - "In conclusion, preclinical data and clinical studies confirm the potential usefulness of radiolabeled lanreotide for tumor diagnosis and therapy. "
3.	Carcinoid Tumor (Carcinoid) 01/01/2004 - "Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide." 09/01/1998 - "In conclusion, prolonged release lanreotide induced clinical and biochemical remission in this patient with diffusely metastatic GHRH-producing carcinoid. " 01/01/2004 - "This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. " 01/01/2014 - "Here, we present a case of poorly differentiated, grade 3 pancreatic NEC associated with carcinoid syndrome, for which adequate symptom control was achieved for 2 years and 4 months using the long-acting SSA lanreotide Autogel(®). " 11/01/2000 - "Lanreotide is safe and well tolerated in patients with carcinoid tumors. "
4.	Pituitary Neoplasms (Pituitary Adenoma) 12/01/2007 - "To evaluate the short-term effects of Lanreotide Autogel on insulin sensitivity markers among acromegalic patients with pituitary tumors. " 01/01/2006 - "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5. " 01/01/2004 - "This variability in sst subtype expression may explain the variable responsiveness of patients with pituitary adenomas to medical treatment with the sst2-preferring SS-analogs octreotide and lanreotide. " 12/01/2002 - "We noticed that the lanreotide caused not only serum level reduction of a growth hormone but also prolactine in patients with mixed pituitary tumors." 10/01/1999 - "Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro."
5.	Neuroendocrine Tumors (Neuroendocrine Tumor) 08/01/2015 - "Lanreotide depot/autogel in neuroendocrine tumors: subgroup analyses from the CLARINET study." 11/15/2006 - "Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study." 10/16/2014 - "Lanreotide in metastatic enteropancreatic neuroendocrine tumors." 10/16/2014 - "Lanreotide in metastatic enteropancreatic neuroendocrine tumors." 10/16/2014 - "Lanreotide in metastatic enteropancreatic neuroendocrine tumors."

Related Drugs and Biologics

1.	Octreotide (Sandostatin)
2.	Somatostatin (Somatotropin Release-Inhibiting Factor)
3.	lanreotide (Somatuline)
4.	Insulin-Like Growth Factor I (IGF-1)
5.	Somatostatin Receptors (Somatostatin Receptor)
6.	pasireotide
7.	vapreotide
8.	Biological Markers (Surrogate Marker)
9.	Hormones
10.	Glucose (Dextrose)

Related Therapies and Procedures

1.	Injections
2.	Subcutaneous Injections
3.	Ligation
4.	Radiotherapy
5.	Intramuscular Injections